SPDR Pharmac

FDA Accepts Viatris Meloxicam NDA, PDUFA Date Set for Dec 2026

LifeSci Capital Analyst Patrick Dolezal Maintains Buy Rating on MBX Biosciences with $91 Target Price

Liquidia Director Stephen M. Bloch Sells 319,000 shares of Common Stock

MBX Biosciences shares fall but analysts raise price targets

Axsome Therapeutics Receives FDA Approval for AUVELITY

Liquidia Tech released FY2026 Q1 earnings on May 11 Pre-Market (EST), actual revenue USD 132.87 M (forecast USD 119.4 M), actual EPS USD 0.5199 (forecast USD 0.41)

Mizuho Raises Axsome Therapeutics Price Target to $310

Esperion Therapeutics released FY2026 Q1 earnings on May 8 Pre-Market (EST), actual revenue USD 80.1 M (forecast USD 84.52 M), actual EPS USD -0.1002 (forecast USD -0.03)

MBX Biosciences released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5099 (forecast USD -0.5847)

Enliven Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.38 (forecast USD -0.4516)

Viatris released FY2026 Q1 earnings on May 7 During-Market (EST), actual revenue USD 3.517 B (forecast USD 3.357 B), actual EPS USD 0.15 (forecast USD -0.8445)

Viatris Q1 2026 Revenue and Earnings Per Share Exceed Expectations

Viatris Reports Q1 2026 Earnings and Reiterates Full-Year Guidance

Oppenheimer Increases Holdings in Axsome Therapeutics

Axsome Therapeutics COO sells 4,750 shares after exercising stock options

Trevi Therapeutics released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0906 (forecast USD -0.0722)

Jazz Pharma released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 1.069 B (forecast USD 979.01 M), actual EPS USD 4.43 (forecast USD 1.828)

Mizuho Securities Maintains Buy Rating on Axsome Therapeutics

BioPharma Credit PLC Announces Financing Allocation for Esperion Transaction

Needham Raises Axsome Therapeutics Target Price to $267

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Cardinal Health Inc. (CAH) shares rose 2.34% to $199.77 on a mixed trading day, marking its fifth consecutive gain. The stock remains 14.48% below its 52-week high of $233.60. Competitors had varied performances, with Amazon up 0.27%, UnitedHealth down 0.69%, and CVS up 0.10%. Trading volume reached 2.4 million, surpassing the 50-day average of 2.0 million.

MarketWatch Automated

Cardinal Health

Invesco Pharmaceuticals ETF

SPDR S&P Health Equip

VanEck Pharmaceutical ETF

iShares US Pharma

iShares US Medical Devices

Dow Jones Industrial Average

S&P 500

Amazon

Unitedhealth

CVS Health

Cardinal Health Inc. Stock Outperforms Competitors On Strong Trading Day

LABU

Wave Life Sciences announced positive results from the RestorAATion-2 trial for WVE-006, showing its potential to treat alpha-1 antitrypsin deficiency (AATD) by generating healthy M-AAT and reducing harmful Z-AAT. The therapy demonstrated sustained effects and safety, with FDA feedback expected by mid-2026. WVE-006 offers advantages over existing treatments, including infrequent dosing and reduced risk of liver inflammation. The trial continues to show promise for addressing both lung and liver manifestations of AATD.

StockTitan

Wave Life Sciences

VG Health

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

Bioshares Biotech Clinical Trials Fd

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing | WVE Stock News

McKesson (MCK) reported strong Q4 and full year earnings, with increased sales and net income, leading to a 1.79% rise in stock price to $760.57. Despite recent declines, long-term returns remain robust. Analysts suggest the stock is undervalued at $951.73, driven by earnings power and acquisitions. However, a DCF model indicates potential downside risk, emphasizing the need to weigh earnings against cash generation. Investors are encouraged to explore other opportunities in healthcare.

Simplywall

McKesson

Assessing McKesson (MCK) Valuation After Strong Q4 And Full Year Earnings Results

Cencora's fiscal Q2 2026 results revealed higher sales of $78.36 billion and net income of $1.64 billion, but a revenue miss and lowered growth outlook have raised concerns about its margin expansion narrative. The company confirmed a 4% to 6% revenue growth guidance for 2026, but ongoing investigations and pricing pressures could impact margins. Analysts are cautious, with some projecting only 4.5% annual growth. Cencora's future performance will be critical in restoring investor confidence and shaping its stock sentiment.

Cencora

Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative?

Pomerantz Law Firm is investigating claims for investors of Cencora, Inc. (NYSE: COR) regarding potential securities fraud by the company and its officers. Following Cencora's Q2 2026 results, which missed revenue estimates and lowered growth guidance, the stock price dropped 17.4%. Investors are encouraged to contact Pomerantz for more information.

prnewswire

22:25 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

Cencora Inc. (COR) shares rose 2.12% to $261.11 on a strong trading day, outperforming competitors like Amazon, UnitedHealth, and CVS. The S&P 500 and Dow Jones also saw gains of 0.77% and 0.75%, respectively. Despite the increase, Cencora remains 30.84% below its 52-week high of $377.54 reached on November 25. Trading volume was significantly higher than its 50-day average.

Factset Research

Cencora Inc. Stock Outperforms Competitors On Strong Trading Day

McKesson Corp. (MCK) shares rose 1.36% to $747.23 on a positive trading day, outperforming competitors like Amazon, UnitedHealth, and CVS. This marks the third consecutive day of gains for McKesson, although it remains 25.20% below its 52-week high of $999.00 reached on March 3rd. The trading volume was 921,594, surpassing the 50-day average of 909,974.

McKesson Corp. Stock Outperforms Competitors On Strong Trading Day

NXPL

NextPlat (NASDAQ:NXPL) reported its Q1 2026 financial results, highlighting significant margin expansion and improved profitability, primarily from its healthcare operations, which contributed 68% of revenue. The company regained compliance with NASDAQ's minimum bid requirement after a reverse stock split. Gross margin increased to 35% from 21% year-over-year, driven by higher-margin revenue streams. NextPlat ended the quarter with $11 million in cash and no significant debt, focusing on sustaining profitability and exploring growth through potential joint ventures or acquisitions.

benzinga_article

NextPlat

SPDR S&P Health

NEXTPLAT CORP C/WTS 02/06/2026 (TO PUR COM)

NextPlat Reports Q1 2026 Results: Full Earnings Call Transcript

NextPlat Corp reported $9.9 million in revenue for Q1 2026, a 29% decrease from the previous year, primarily due to lower healthcare revenue. However, the company achieved a record gross margin of 35%, up from 21% year-over-year, driven by improved pharmacy operations and new contracts. Operating expenses decreased by 9% to $4.5 million, reflecting ongoing cost-cutting measures. The CEO expressed optimism about future growth and profitability, anticipating positive income from operations in the latter half of 2026 as the company continues its turnaround efforts.

08:01 ETNextPlat Reports $9.9 Million in Revenue for Q1 2026 with Record Quarterly Consolidated Gross Margins of 35%

Are Wall Street Analysts Bullish on Cencora Stock?

Barchart Option